People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Yaupon Therapeutics Inc | — | Pharmaceuticals | Series A | $21.6M | $256.8M | 2011 |
Doug Gessl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Doug Gessl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert Cha | 1 | 9 |
| Stephen Tullman | 1 | 7 |
| James Huang | 1 | 5 |
| Douglas Gessl | 1 | 4 |
| Kamil Ali-Jackson | 1 | 3 |
| Greg Vontz | 1 | 3 |
| Thomas P. Hess | 1 | 2 |
| William Hamilton | 1 | 2 |
| John Doux | 1 | 2 |
| William F. Hamilton | 1 | 2 |
| David C. Drahms | 1 | 1 |
| Timothy Henkel | 1 | 1 |
| David Drahams | 1 | 1 |
| Evan Dick | 1 | 1 |
| H. Jeffrey Wilkins | 1 | 1 |
| Jeff Wilkins | 1 | 1 |
| Robert J. Alonso | 1 | 1 |
| Greg F. Vontz | 1 | 1 |
| James F. Huang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.